CollPlant Biotechnologies (CLGN) Cash from Investing Activities (2018 - 2026)
CollPlant Biotechnologies (CLGN) reported Cash from Investing Activities of -$6000.0 for Q1 2026, up 25.0% on a YoY basis from -$4800.0 in Q1 2025, and up 60.0% quarter-over-quarter from -$15000.0 in Q4 2025.
CollPlant Biotechnologies (CLGN) Cash from Investing Activities (2018 - 2026) Analysis & Trends
CollPlant Biotechnologies has reported Cash from Investing Activities for 9 years, with the latest figure at -$6000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 25.0% year-over-year to -$6000.0; the trailing twelve-month figure through Mar 2026 stood at -$25000.0 (up 94.62% YoY), and the FY2025 full-year result was -$27000.0, up 94.99% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$6000.0, up from -$15000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $29.9 million in Q1 2022, with the low at -$396000.0 in Q2 2023.
- Historically, Cash from Investing Activities has averaged $1.6 million across 5 years, with a median of -$140000.0 in 2024.
- The largest YoY upside for Cash from Investing Activities was 199.03% in 2022 against a maximum downside of 103.44% in 2022.
- CollPlant Biotechnologies' Cash from Investing Activities stood at -$304000.0 in 2022, then retreated by 22.37% to -$372000.0 in 2023, then surged by 84.41% to -$58000.0 in 2024, then jumped by 74.14% to -$15000.0 in 2025, then soared by 60.0% to -$6000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$6000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$1000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 579,519.10 |
| 10 | CollPlant Biotechnologies | 7.20 Mn | 7.20 Mn | - | -6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,000.00 |
| Mar 31, 2026 | -6,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -58,000.00 |
| Dec 31, 2024 | -58,000.00 |
| Sep 30, 2024 | -140,000.00 |
| Sep 30, 2024 | -140,000.00 |
| Jun 30, 2024 | -259,000.00 |
| Jun 30, 2024 | -259,000.00 |
| Mar 31, 2024 | -82,000.00 |
| Mar 31, 2024 | -82,000.00 |
| Dec 31, 2023 | -372,000.00 |
| Dec 31, 2023 | -372,000.00 |